Supporting Patient Care, AminoProtect®
Produced Through State-of-the-Art cGMP Compliant Operations
Fagron Sterile Services US (FSS) offers health systems, hospitals, ambulatory surgery centers, and physician offices reliable 503B Outsourcing solutions to support critical care, labor and delivery, pain management, ophthamlics (including Avastin®), and other specialty medication like the only sterile LET gel, a topical anesthetic.
FSS is proud to continue to expand its product portfolio to support patient care needs with the addition of AminoProtect® IV bags produced through cGMP-compliant operations.
As the only vertically integrated 503B outsourcing partner to patient-focused healthcare facilities in the US, FSS is part of the global network of Fagron companies serving over 35 countries. This uniquely positions FSS to better support the healthcare supply chain. Fagron is the global leader in pharmaceutical compounding, with over 30 years of experience creating the future of personalizing medicine.
"At FSS, we are always looking for unique products that advance the wellbeing of patients. Providing AminoProtect® is an opportunity to help patients during a challenging time when they are battling a terrible disease," said Erika Lafluer, Senior Director of Sales for Fagron Sterile Services US.
FSS continues to invest in New Product Development and innovation to support increasing customer demand for its 503B outsourcing services. Recently the business announced plans to more than double its operational footprint and will begin offering RFID-enabled ready-to-administer OR syringes in collaboration with Kit Check.
Learn more and request a free consultation today!
About Fagron Sterile Services US
As an industry-leading, 503B Outsourcing Facility, Fagron Sterile Services US (FSS), supports patient-focused healthcare facilities across North America with a reliable supply of critical high-quality sterile medications produced through cGMP-compliant operations.
The FSS team includes operational and regulatory expertise in pharmaceutical manufacturing and repackaging while leveraging industry-leading automation, advanced environmental monitoring, and sophisticated in-house quality testing labs. Batches are validated to support proper Beyond-Use Dating (BUD) and are only released after successful sterility, particulate matter, and potency testing are complete.
A broad product portfolio includes ready-to-administer critical care, labor and delivery, pain management, ophthamlics (including Avastin®), and other specialty medications like the only sterile LET gel, a topical anesthetic. As a trusted 503B outsourcing partner, FSS holds Integrated Delivery Network (IDN) agreements within all major GPOs.